MedTrace Logo

Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma

NCT00145158 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2022-10-10

Study results available
· View outcomes & findings →

Summary

The purposes of this study are to describe the immune response to individual peptides after immunization with a combination of 8 peptides and CpG 7909 or Montanide ISA51; to determine the safety of the vaccines and; to document the tumor response in patients receiving the vaccines.

Conditions

  • Malignant Melanoma

Interventions

BIOLOGICAL

8 HLA-A2-restricted peptides and Montanide ISA51

BIOLOGICAL

8 HLA-A2-restricted peptides and CpG 7909

Sponsors & Collaborators

  • Ludwig Institute for Cancer Research

    lead OTHER

Principal Investigators

  • Nicolas VanBaren, MD · Ludwig Institute for Cancer Research

  • Thierry BOON, PhD · Ludwig Institute for Cancer Research

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2007-11-30
Completion
2009-03-12

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00145158 on ClinicalTrials.gov